Rituximab and Low White Blood Cells: MS Patient Guide

Credibility

Interest

Share:2 min read

Key Takeaway

Serious drops in infection-fighting white blood cells were uncommon after rituximab, but checking blood counts and watching for infection symptoms remain important.

What They Found

Researchers followed 2,686 people with MS in Sweden who received rituximab for nearly eight years on average. About 6% had late-onset neutropenia, meaning a delayed drop in neutrophils, the white blood cells that help fight infections. Most cases were mild and caused no major health problems, but about 1% had a severe drop in these cells. Ten severe cases included infections, and all affected people recovered with hospital care, infection-fighting medicines, and sometimes treatment to help the body make more neutrophils. Rituximab was restarted after 89% of severe events, and some people had another blood-cell drop, but serious complications after restarting were uncommon.

Who Should Care and Why

This study matters most to people with MS taking rituximab or other medicines that lower certain immune cells. A low neutrophil count can be like having fewer security guards protecting the body, so fever, chills, sore throat, or other infection signs should be reported quickly. Caregivers can help by watching for these symptoms and reminding loved ones about scheduled blood tests. Healthcare providers may use blood-count checks and infection education to make treatment safer, especially after rituximab has been started. Most patients should not assume they need to stop treatment, because severe problems were rare and many people recovered with proper care.

Important Considerations

The study looked back at medical records, so it could show patterns but cannot prove that rituximab alone caused every blood-cell change or infection. It was done in Sweden, and the results may not apply exactly to people with different health conditions, treatments, or access to care. Researchers could not reliably predict who would develop neutropenia, so regular monitoring and attention to infection symptoms remain important.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Specific Symptoms MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology(R) neuroimmunology & neuroinflammation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News